Aclarion Inc (ACON) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Aclarion Inc stock (ACON) is currently trading at $3.45. Aclarion Inc PS ratio (Price-to-Sales) is 50.00. Analyst consensus price target for ACON is $22.00. WallStSmart rates ACON as Sell.
- ACON PE ratio analysis and historical PE chart
- ACON PS ratio (Price-to-Sales) history and trend
- ACON intrinsic value — DCF, Graham Number, EPV models
- ACON stock price prediction 2025 2026 2027 2028 2029 2030
- ACON fair value vs current price
- ACON insider transactions and insider buying
- Is ACON undervalued or overvalued?
- Aclarion Inc financial analysis — revenue, earnings, cash flow
- ACON Piotroski F-Score and Altman Z-Score
- ACON analyst price target and Smart Rating
Aclarion Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Aclarion Inc (ACON) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Aclarion Inc (ACON) Key Strengths (2)
Trading below book value, meaning the market prices it less than net assets
Revenue surging 76.10% year-over-year
Supporting Valuation Data
Aclarion Inc (ACON) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Very expensive at 50.0x annual revenue
Very low institutional interest at 1.65%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Aclarion Inc (ACON) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 1.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Revenue Growth. Valuation metrics including Price/Book (0.27) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 76.10%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (50.00) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -88.30%, Operating Margin at -8989.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -88.30% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 76.10% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ACON Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ACON's Price-to-Sales ratio of 50.00x trades 60% above its historical average of 31.29x (72th percentile), historically expensive. The current valuation is 68% below its historical high of 154.37x set in Mar 2025, and 4487% above its historical low of 1.09x in Dec 2024. Over the past 12 months, the PS ratio has compressed from ~154.4x as trailing revenue scaled faster than the stock price.
Compare ACON with Competitors
Top HEALTH INFORMATION SERVICES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Aclarion Inc (ACON) · HEALTHCARE › HEALTH INFORMATION SERVICES
The Big Picture
Aclarion Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 62,950 with 76% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 76% YoY, reaching 62,950. This pace significantly outperforms most HEALTH INFORMATION SERVICES peers.
Spending 1642237060% of revenue (1.0T) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Aclarion Inc maintain 76%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor HEALTH INFORMATION SERVICES industry trends, competitive moves, and regulatory changes that could impact Aclarion Inc.
Bottom Line
Aclarion Inc is a high-conviction growth story with revenue accelerating at 76% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Aclarion Inc(ACON)
NASDAQ
HEALTHCARE
HEALTH INFORMATION SERVICES
USA
Aclarion Inc (ACON) is an innovative healthcare technology company specializing in non-invasive diagnostic solutions that harness advanced data analytics and machine learning. By optimizing treatment pathways for musculoskeletal conditions, Aclarion delivers actionable insights derived from cutting-edge imaging techniques. Positioned at the forefront of the digital health sector, the company is addressing significant challenges in patient management while enhancing outcomes and reducing costs. Aclarion is well-positioned to capitalize on the growing demand for effective diagnostic tools in a dynamic healthcare landscape.